Comparison of sensitivity to various drugs between erlotinib- and gefitinib- resistant cell lines and their drug sensitive parental counterparts, PC9 and 11–18 cells.
- Keisuke Tabara (150758)
- Rina Kanda (150763)
- Kahori Sonoda (150767)
- Takuya Kubo (150771)
- Yuichi Murakami (150775)
- Akihiko Kawahara (150779)
- Koichi Azuma (150783)
- Hideyuki Abe (34795)
- Masayoshi Kage (150786)
- Aki Yoshinaga (150789)
- Tomoko Tahira (23929)
- Kenshi Hayashi (23930)
- Tokuzo Arao (150793)
- Kazuto Nishio (150795)
- Rafael Rosell (145450)
- Michihiko Kuwano (150798)
- Mayumi Ono (150799)
Publication date
July 2012
DOIAbstract
a)<p>IC50 values are calulated from logit regression line from triplicate assays. IC50 values (µM) for erlotinib, gefitinib, lapatinib, SU11274, BIBW2992 and cisplatin are 0.04, 0.03, 3.16, 3.97, 0.00021 and 2.07 in PC9, 9.96, 5.04, 14.54, 3.97, 0.41 and 2.89 in PC9/ER1, 0.87, 0.32, 2.57, 4.22, 0.35 and 5.37 in 11–18, 20.88, 8.32, 2.83, 4.64, 0.49 and 1.61 in 11–18/ER1-7, 95.7, 20.48, 4.11, 5.06, 0.74 and 9.13 in 11–18/ER2-1, >29.58, 11.52, 13.36, 3.38 and 2.41 in 11–18/GEF10-1, and >29.58, 10.24, 14.14, 3.80 and 1.61 in 11–18/GEF20-1 respectively. The relative resistance is defined as the IC50 value divided by the IC50 value of the parental PC9 or 11–18.</p>b)<p>nt, not tested.</p
Add to ORKG